May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Evaluation of Bevacizumab Cytotoxicity on Human Corneal Cell Lines
Author Affiliations & Notes
  • M. G. Roberts
    Ophthalmology, University of Florida, Jacksonville, Florida
  • R. K. Sharma
    Ophthalmology, University of Florida, Jacksonville, Florida
  • C. N. Nagineni
    Ophthalmology, University of Florida, Jacksonville, Florida
  • A. Grover
    Bolles School, Jacksonville, Florida
  • K. V. Chalam
    Ophthalmology, University of Florida, Jacksonville, Florida
  • Footnotes
    Commercial Relationships  M.G. Roberts, None; R.K. Sharma, None; C.N. Nagineni, None; A. Grover, None; K.V. Chalam, None.
  • Footnotes
    Support  Departmental
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1486. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. G. Roberts, R. K. Sharma, C. N. Nagineni, A. Grover, K. V. Chalam; Evaluation of Bevacizumab Cytotoxicity on Human Corneal Cell Lines. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1486.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Corneal neovascularization occurs in several conditions, including inflammatory, infectious, degenerative, traumatic, and iatrogenic processes. Blood vessels infiltrate the cornea from the limbal vascular plexus. Vascular Endothelial Growth Factor (VEGF) plays an important role in stimulating and maintaining corneal neovascularization. Bevacizumab is a full length recombinant humanized monoclonal antibody that binds to VEGF, and it is being successfully used as anti-VEGF therapy. The promising outlook of this anti-VEGF therapy has prompted the off- label topical use of bevacizumab for corneal neovascularization. Whether such a therapy has any adverse effect on the corneal cells is not well studied. In this study, we investigated the effect bevacizumab on corneal and vascular endothelial cells in culture.

Methods: : Human corneal epithelial (HCE), human corneal fibroblast (HCRF) cell lines, and human umbilical vein endothelial (HUVEC) cell line, representing cells likely to exposed in topical treatment were used in the study. Cells were exposed to increasing doses (0.1, 1 and 2 mg/ml) of bevacizumab. Cytotoxic and proliferative effects of this treatment were assessed by quantifying the cell numbers by WST-1 and crystal violet staining. Cell death was also assessed by flow cytometry and fluorescent microscopy using propidium iodide staining.

Results: : There were no cytotoxic effects of bevacizumab seen in any of the three cell lines (p <0.05). Flow cytometric analysis and fluorescent microscopy supported these results. There was a dose dependant effect on proliferation on all three cell lines. HCRF proliferation increased up to 26% (SE 3.7; p <0.001), HCE up to 24% (SE 4.5; p <0.005) and HUVEC up to 37% (SE 10.6; p <0.01) with 2 mg/ml bevacizumab treatment as assessed with WST-1. Crystal violet assessment showed HCRF proliferation increased up to 35% (SE 2.4; p <0.0001), HCE up to 45% (SE 5.4; p <0 .001) and HUVEC up 8% (SE 2.3; p <0.01) with 2 mg/ml bevacizumab treatment.

Conclusions: : Bevacizumab was not cytotoxic to human corneal fibroblast and epithelial cells nor to human umbilical vein endothelial cells. All three cell lines showed evidence of proliferation upon exposure to bevacizumab.

Keywords: cornea: basic science • neovascularization • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×